Tilray Brands, Inc. (2HQ.DE)
EUR 0.41
(-3.15%)
EUR 0.41
(-3.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -244.98 Million USD | 83.14% |
| 2022 | -1.45 Billion USD | -204.67% |
| 2021 | -476.8 Million USD | -29.77% |
| 2020 | -367.42 Million USD | -258.32% |
| 2019 | -102.54 Million CAD | -309.55% |
| 2018 | -25.03 Million CAD | -210.25% |
| 2017 | 22.71 Million CAD | 630.7% |
| 2016 | 3.1 Million CAD | 922.79% |
| 2015 | 303.87 Thousand CAD | 105.81% |
| 2014 | -5.23 Million CAD | -293.05% |
| 2013 | -1.33 Million USD | -120.3% |
| 2012 | -604.51 Thousand CAD | -526.91% |
| 2011 | -96.42 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -39.16 Million USD | 53.38% |
| 2023 Q1 | -55.86 Million USD | 59.73% |
| 2023 Q4 | -31.74 Million USD | 65.75% |
| 2023 Q3 | -92.7 Million USD | -43.34% |
| 2023 FY | -244.98 Million USD | 83.02% |
| 2023 Q2 | -64.67 Million USD | -15.77% |
| 2022 Q4 | -138.71 Million USD | 88.15% |
| 2022 FY | -1.44 Billion USD | -232.39% |
| 2022 Q3 | -1.17 Billion USD | -1417.8% |
| 2022 Q2 | -77.15 Million USD | -17.26% |
| 2022 Q1 | -65.79 Million USD | 86.24% |
| 2021 FY | -434.13 Million USD | -29.2% |
| 2021 Q4 | -478.14 Million USD | -1207.06% |
| 2021 Q1 | -41.64 Million USD | -203.24% |
| 2021 Q3 | 43.19 Million USD | 21587.56% |
| 2021 Q2 | -201 Thousand USD | 99.52% |
| 2020 Q3 | -273.51 Million CAD | -173.79% |
| 2020 Q2 | -99.9 Million USD | -190.89% |
| 2020 FY | -336.01 Million USD | -450.69% |
| 2020 Q4 | 40.34 Million USD | 114.75% |
| 2020 Q1 | -34.34 Million USD | 69.56% |
| 2019 Q2 | -5.96 Million USD | -148.53% |
| 2019 Q3 | -184.12 Million USD | -2984.41% |
| 2019 Q4 | -112.83 Million USD | 38.72% |
| 2019 FY | -61.01 Million CAD | -400.36% |
| 2019 Q1 | 12.3 Million USD | 5.51% |
| 2018 Q1 | 16.22 Million USD | 521.51% |
| 2018 FY | -12.19 Million CAD | -153.4% |
| 2018 Q4 | 11.65 Million USD | 114.18% |
| 2018 Q3 | -82.23 Million USD | -299.47% |
| 2018 Q2 | 41.22 Million USD | 154.05% |
| 2017 Q4 | -3.84 Million USD | -138.16% |
| 2017 FY | 22.83 Million CAD | 632.79% |
| 2017 Q3 | 10.08 Million USD | 101.61% |
| 2017 Q1 | 12.04 Million USD | 727.44% |
| 2017 Q2 | 5 Million USD | -58.46% |
| 2016 FY | 3.11 Million CAD | 921.38% |
| 2016 Q4 | -1.91 Million USD | -151.51% |
| 2016 Q1 | 682.6 Thousand CAD | -31.35% |
| 2016 Q3 | 3.72 Million USD | 429.67% |
| 2016 Q2 | 703.65 Thousand CAD | 3.08% |
| 2015 Q1 | -359.63 Thousand CAD | 6.61% |
| 2015 Q3 | 2749.08 CAD | 100.85% |
| 2015 Q4 | 994.29 Thousand CAD | 36068.43% |
| 2015 FY | 305.12 Thousand CAD | 105.8% |
| 2015 Q2 | -323.44 Thousand CAD | 10.06% |
| 2014 Q4 | -385.08 Thousand CAD | 84.47% |
| 2014 Q3 | -2.48 Million CAD | -108.26% |
| 2014 Q2 | -1.19 Million CAD | 19.2% |
| 2014 Q1 | -1.47 Million CAD | -141.42% |
| 2014 FY | -5.26 Million CAD | -295.35% |
| 2013 Q3 | -272.38 Thousand CAD | -26.38% |
| 2013 Q4 | -610.47 Thousand CAD | -124.12% |
| 2013 Q1 | -6954.06 CAD | -89.61% |
| 2013 FY | -1.33 Million USD | -3071.66% |
| 2013 Q2 | -215.52 Thousand CAD | -2999.27% |
| 2012 Q1 | -12.76 Thousand CAD | 25.74% |
| 2012 Q2 | -19.48 Thousand CAD | -52.65% |
| 2012 Q3 | -12.67 Thousand CAD | 34.95% |
| 2012 FY | -41.98 Thousand CAD | 56.46% |
| 2012 Q4 | -3667.48 CAD | 71.07% |
| 2011 Q4 | -17.18 Thousand CAD | 73.7% |
| 2011 Q3 | -65.34 Thousand CAD | -1808.27% |
| 2011 FY | -96.42 Thousand CAD | 0.0% |
| 2011 Q2 | -3424.37 CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| MPH Health Care AG | 29.54 Million EUR | 929.193% |
| Apontis Pharma AG | -11.3 Million EUR | -2067.407% |
| Dermapharm Holding SE | 62.36 Million EUR | 492.799% |
| Evotec SE | -83.91 Million EUR | -191.946% |
| MERCK Kommanditgesellschaft auf Aktien | 2.82 Billion EUR | 108.675% |
| PharmaSGP Holding SE | 16.39 Million EUR | 1594.06% |
| SynBiotic SE | -10.63 Million EUR | -2204.49% |